9 completed, 3 terminated, 1 not yet recruiting, 1 recruiting. 10 Phase 2, 2 Early Phase 1, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Terminated 2, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Early Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Discoid Lupus Erythematosus: new trials by email Literature Review of Discoid Lupus Erythematosus trials Research Report on Discoid Lupus Erythematosus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus Dihydroartemisinin tablets, Hydroxychloroquine tablets - Discoid Lupus Erythematosus | Phase 2 | Not yet recruiting | Kunming Pharmaceuticals, Inc. | 100 | 2026-04-30 | 2026-04-30 |
| Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus Ruxolitinib 1.5% cream, Application without occlusion in Area 1, Application under occlusion at night in Area 2 - Discoid Lupus Erythematosus | Phase 2 | Recruiting | Innovaderm Research Inc. | 20 | 2024-04-19 | 2025-03-24 |
| Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus Placebo, Daxdilimab - Discoid Lupus Erythematosus | Phase 2 | Terminated | Amgen | 72 | 2022-12-29 | 2026-05-14 |
| Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus Ruxolitinib - Discoid Lupus Erythematosus | Phase 2 | Completed | University of Rochester | 10 | 2022-05-04 | 2025-05-20 |
| Topical Nicotinamide in Treatment of DLE Nicotinamide Topical - Discoid Lupus Erythematosus | Early Phase 1 | Completed | Al-Azhar University | 60 | 2022-03-01 | 2022-10-25 |
| A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus Secukinumab - Discoid Lupus Erythematosus | Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-09-01 | 2021-09-08 | |
| Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. Delgocitinib cream, Delgocitinib cream vehicle - Discoid Lupus Erythematosus | Phase 2 | Terminated | LEO Pharma | 27 | 2019-07-09 | 2025-03-06 |
| Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Tofacitinib citrate - Discoid Lupus Erythematosus, Systemic Lupus Erythematosus | Early Phase 1 | Terminated | Tufts Medical Center | 5 | 2017-04-03 | 2022-01-21 |
| Pilot Tape Harvesting Study Skin Taping, Blood Sampling, Skin Biopsy - Atopic Dermatitis, Healthy | Completed | Biogen | 37 | 2014-05-01 | 2016-09-28 | |
| Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients CC-10004 - Discoid Lupus Erythematosus | Phase 1 / Phase 2 | Completed | NYU Langone Health | 8 | 2008-06-01 | 2021-03-03 |
| Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions ASF 1096 0.5 % cream applied twice daily, Cream vehicle for ASF 1096 cream applied twice daily - Discoid Lupus Erythematosus | Phase 2 | Completed | Astion Pharma A/S | 32 | 2006-11-01 | 2008-02-29 |
| Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia Central Centrifugal Scarring Alopecia, Lichen Planopilaris | Completed | Wake Forest University | 8 | 2006-04-26 | 2018-07-06 | |
| Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus Pimecrolimus 1% cream, betamethasone valerate 0.1% cream - Discoid Lupus Erythematosus | Not applicable | Completed | Shahid Beheshti University of Medical Sciences | 10 | 2006-04-01 | 2008-02-15 |
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Thalidomide - Discoid Lupus Erythematosus | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 1997-10-01 | 2008-03-04 |
| Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) ASF 1096 0.5 % cream, ASF 1096 placebo cream - Discoid Lupus Erythematosus | Phase 2 | Completed | Astion Pharma A/S | 2008-02-29 |
Lupus Erythematosus, Discoid (15) · Lupus Erythematosus, Cutaneous (2) · Alopecia (1) · Connective Tissue Diseases (1) · Dermatitis, Atopic (1) · Immune System Diseases (1) · Lichen Planus (1) · Lupus Erythematosus, Systemic (1) · Skin Diseases (1)
Skin and Connective Tissue Diseases (15) · Connective Tissue Diseases (14) · Skin Diseases (14) · Lupus Erythematosus, Cutaneous (13) · Immune System Diseases (2) · Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1) · Genetic Diseases, Inborn (1) · Hair Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Hypotrichosis (1) · Lichenoid Eruptions (1) · Pathological Conditions, Anatomical (1)
ruxolitinib (2) · Betamethasone Valerate (1) · Blood Specimen Collection (1) · Hydroxychloroquine (1) · Niacinamide (1) · Salicylic Acid (1) · Thalidomide (1) · apremilast (1) · artenimol (1) · pimecrolimus (1) · secukinumab (1) · tofacitinib (1)
Astion Pharma A/S (2) · Al-Azhar University (1) · Amgen (1) · Biogen (1) · Innovaderm Research Inc. (1) · Kunming Pharmaceuticals, Inc. (1) · LEO Pharma (1) · Massachusetts General Hospital (1) · NYU Langone Health (1) · National Cancer Institute (NCI) (1) · Shahid Beheshti University of Medical Sciences (1) · Tufts Medical Center (1) · University of Rochester (1) · Wake Forest University (1)
United States (9) · Denmark (3) · Canada (2) · France (2) · Germany (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · China (1) · Czechia (1) · Egypt (1) · Greece (1) · Iran (1) · Poland (1) · Sweden (1)
Ahmed Hassan Nouh, MD (1) · Amy McMichael, MD (1) · Andrew G Franks, Jr., MD (1) · Behrooz Barikbin, M.D. (1) · Christopher T Richardson, MD, PhD (1) · David Rosmarin, MD (1) · Gideon Smith, MD (1) · Robert Bissonnette, MD (1) · Yong Cui, MD (1)
2018 (1), 2023 (1)